The role of radioiodine therapy in benign nodular goitre

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 28, Issue 4, 2014, Pages 619-631

  Bonnema, Steen Joop ^a   Fast, Søren ^b   Hegedüs, Laszlo ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b LILLEBAELT HOSPITAL   (Denmark)

Author keywords

nodular goitre; radioiodine; recombinant human thyrotropin; thyroid diseases

Indexed keywords

RADIOACTIVE IODINE; RECOMBINANT PROTEIN; THYROTROPIN;

COMPUTER ASSISTED RADIOTHERAPY; DECISION MAKING; GOITER, NODULAR; HUMAN; ORGAN SIZE; PATHOLOGY; PROCEDURES; THYROIDECTOMY; UTILIZATION;

CHOICE BEHAVIOR; GOITER, NODULAR; HUMANS; IODINE RADIOISOTOPES; ORGAN SIZE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RECOMBINANT PROTEINS; THYROIDECTOMY; THYROTROPIN;

EID: 84904724270     PISSN: 1521690X     EISSN: 15321908     Source Type: Journal    
DOI: 10.1016/j.beem.2014.02.001     Document Type: Review

References (99)

1. L. Hegedüs, B.M. Hansen, and N. Knudsen et al. Reduction of size of thyroid with radioactive iodine in multinodular non-toxic goitre Br Med J 297 1988 661 662
2. S.J. Bonnema, F.N. Bennedbæk, and W.M. Wiersinga et al. Management of the nontoxic multinodular goitre: a European questionnaire study Clin Endocrinol 53 2000 5 12
3. H. Gharib, E. Papini, and R. Paschke et al. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules J Endocrinol Investigation 33 2010 1 50
4. R. Paschke, L. Hegedüs, and E. Alexander et al. Thyroid nodule guidelines: agreement, disagreement and need for future research Nat Rev Endocrinol 7 2011 354 361
5. M.I. Surks, E. Ortiz, and G.H. Daniels et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management JAMA: J Am Med Assoc 291 2004 228 238
6. S. Fast, S.J. Bonnema, and L. Hegedüs The majority of Danish nontoxic goitre patients are ineligible for levothyroxine suppressive therapy Clin Endocrinol 69 2008 653 658
7. M.F. Wesche, M.M. Tiel-Van Buul, and P. Lips et al. A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter J Clin Endocrinol Metabolism 86 2001 998 1005
8. N.J. Gittoes, M.R. Miller, and J. Daykin et al. Upper airways obstruction in 153 consecutive patients presenting with thyroid enlargement Br Med J 312 1996 484
9. P.V. Pradeep, P. Tiwari, and A. Mishra et al. Pulmonary function profile in patients with benign goiters without symptoms of respiratory compromise and the early effect of thyroidectomy J Postgrad Med 54 2008 98 101
10. L. Hegedüs, S.J. Bonnema, and F.N. Bennedbæk Management of simple nodular goiter: current status and future perspectives Endocr Rev 24 2003 102 132
11. S.J. Bonnema, V.E. Nielsen, and L. Hegedüs Long-term effects of radioiodine on thyroid function, size and patient satisfaction in non-toxic diffuse goitre Eur J Endocrinol 150 2004 439 445
12. T. Watt, M. Grønvold, and A.K. Rasmussen et al. Quality of life in patients with benign thyroid disorders. A review Eur J Endocrinol 154 2006 501 510
13. M. Dietlein, K.W. Lauterbach, and H. Schicha Treatment of toxic nodular goitres: comparative costing of radioiodine therapy and surgery Exp Clin Endocrinol Diabetes 106 Suppl. 4 1998 S66 S70
14. S.J. Bonnema, and L. Hegedüs Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome Endocr Rev 33 2012 920 980
15. C. Greenlee, L.A. Burmeister, and R.S. Butler et al. Current safety practices relating to I-131 administration for diseases of the thyroid: a survey of physicians and allied practitioners Thyroid 21 2011 151 160
16. S.J. Bonnema, H. Bertelsen, and J. Mortensen et al. The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function J Clin Endocrinol Metabolism 84 1999 3636 3641
17. V.E. Nielsen, S.J. Bonnema, and H. Boel-Jørgensen et al. Stimulation with 0.3-mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign nontoxic nodular goiter: a prospective randomized double-blind trial Archives Intern Med 166 2006 1476 1482
18. S.J. Bonnema, V.E. Nielsen, and H. Boel-Jørgensen et al. Improvement of goiter volume reduction after 0.3 mg recombinant human thyrotropin-stimulated radioiodine therapy in patients with a very large goiter: a double-blinded, randomized trial J Clin Endocrinol Metabolism 92 2007 3424 3428
19. J.M. De Klerk, J.W. Van Isselt, and A. van Dijk et al. Iodine-131 therapy in sporadic nontoxic goiter J Nucl Med 38 1997 372 376
20. R. Le Moli, M.F. Wesche, and M.M. Tiel-Van Buul et al. Determinants of longterm outcome of radioiodine therapy of sporadic non- toxic goitre Clin Endocrinol 50 1999 783 789
21. J. Bachmann, C. Kobe, and S. Bor et al. Radioiodine therapy for thyroid volume reduction of large goitres Nucl Med Commun 30 2009 466 471
22. D.A. Huysmans, A.R. Hermus, and F.H. Corstens et al. Large, compressive goiters treated with radioiodine Ann Intern Med 121 1994 757 762
23. B. Nygaard, L. Hegedüs, and M. Gervil et al. Radioiodine treatment of multinodular non-toxic goitre Br Med J 307 1993 828 832
24. J. Verelst, M. Bonnyns, and D. Glinoer Radioiodine therapy in voluminous multinodular non-toxic goitre Acta Endocrinol 122 1990 417 421
25. D. Huysmans, A. Hermus, and M. Edelbroek et al. Radioiodine for nontoxic multinodular goiter Thyroid 7 1997 235 239
26. B. Nygaard, L. Hegedüs, and P. Ulriksen et al. Radioiodine therapy for multinodular toxic goiter Archives Intern Med 159 1999 1364 1368
27. B. Nygaard, L. Hegedüs, and K.G. Nielsen et al. Long-term effect of radioactive iodine on thyroid function and size in patients with solitary autonomously functioning toxic thyroid nodules Clin Endocrinol 50 1999 197 202
28. D.S. Ross, E.C. Ridgway, and G.H. Daniels Successful treatment of solitary toxic thyroid nodules with relatively low-dose iodine-131, with low prevalence of hypothyroidism Ann Intern Med 101 1984 488 490
29. S. Metso, P. Jaatinen, and H. Huhtala et al. Long-term follow-up study of radioiodine treatment of hyperthyroidism Clin Endocrinol 61 2004 641 648
30. S.J. Bonnema, F.N. Bennedbæk, and A. Veje et al. Propylthiouracil before 131I therapy of hyperthyroid diseases: effect on cure rate evaluated by a randomized clinical trial J Clin Endocrinol Metabolism 89 2004 4439 4444
31. M.A. Walter, M. Briel, and M. Christ-Crain et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials Br Med J 334 2007 514
32. C. Ceccarelli, W. Bencivelli, and P. Vitti et al. Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years' retrospective study Clin Endocrinol 62 2005 331 335
33. S.J. Bonnema, D.U. Knudsen, and H. Bertelsen et al. Does radioiodine therapy have an equal effect on substernal and cervical goiter volumes? Evaluation by magnetic resonance imaging Thyroid 12 2002 313 317
34. L. Hegedüs, and S.J. Bonnema Approach to management of the patient with primary or secondary intrathoracic goiter J Clin Endocrinol Metabolism 95 2010 5155 5162
35. S.J. Bonnema, F.N. Bennedbæk, and J. Gram et al. Resumption of methimazole after 131I therapy of hyperthyroid diseases: effect on thyroid function and volume evaluated by a randomized clinical trial Eur J Endocrinol 149 2003 485 492
36. S.J. Bonnema, V.E. Nielsen, and H. Boel-Jørgensen et al. Recombinant human thyrotropin-stimulated radioiodine therapy of large nodular goiters facilitates tracheal decompression and improves inspiration J Clin Endocrinol Metabolism 93 2008 3981 3984
37. B. Nygaard, J. Faber, and L. Hegedüs Acute changes in thyroid volume and function following 131I therapy of multinodular goitre Clin Endocrinol 41 1994 715 718
38. S. Kinuya, T. Yoneyama, and T. Michigishi Airway complication occurring during radioiodine treatment for Graves' disease Ann Nucl Med 21 2007 367 369
39. B. Nygaard, R.A. Metcalfe, and J. Phipps et al. Graves' disease and thyroid associated ophthalmopathy triggered by 131I treatment of non-toxic goiter J Endocrinol Investigation 22 1999 481 485
40. B. Nygaard, L. Hegedüs, and M. Gervil et al. Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism in Graves' disease J Intern Med 238 1995 491 497
41. J.A. Franklyn, P. Maisonneuve, and M.C. Sheppard et al. Mortality after the treatment of hyperthyroidism with radioactive iodine New Engl J Med 338 1998 712 718
42. J.A. Franklyn, M.C. Sheppard, and P. Maisonneuve Thyroid function and mortality in patients treated for hyperthyroidism JAMA: J Am Med Assoc 294 2005 71 80
43. S. Metso, P. Jaatinen, and H. Huhtala et al. Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism J Clin Endocrinol Metabolism 92 2007 2190 2196
44. S. Metso, A. Auvinen, and J. Salmi et al. Increased long-term cardiovascular morbidity among patients treated with radioactive iodine for hyperthyroidism Clin Endocrinol 68 2008 450 457
45. F. Brandt, D. Almind, and K. Christensen et al. Excess mortality in hyperthyroidism: the influence of preexisting comorbidity and genetic confounding: a danish nationwide register-based cohort study of twins and singletons J Clin Endocrinol Metabolism 97 2012 4123 4129
46. F. Brandt, M. Thvilum, and D. Almind et al. Morbidity before and after the diagnosis of hyperthyroidism: a nationwide register-based study PLoS One 8 2013 e66711
47. F. Brandt, M. Thvilum, and D. Almind et al. Graves' disease and toxic nodular goiter are both associated with increased mortality but differ with respect to the cause of death: a Danish population-based register study Thyroid 23 2013 408 413
48. T. Angusti, A. Codegone, and R. Pellerito et al. Thyroid cancer prevalence after radioiodine treatment of hyperthyroidism J Nucl Med 41 2000 1006 1009
49. J.A. Franklyn, P. Maisonneuve, and M. Sheppard et al. Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study Lancet 353 1999 2111 2115
50. P. Hall, G. Berg, and G. Bjelkengren et al. Cancer mortality after iodine-131 therapy for hyperthyroidism Int J Cancer 50 1992 886 890
51. E. Ron, M.M. Doody, and D.V. Becker et al. Cancer mortality following treatment for adult hyperthyroidism. Cooperative thyrotoxicosis therapy follow-up study group JAMA: J Am Med Assoc 280 1998 347 355
52. S. Metso, A. Auvinen, and H. Huhtala et al. Increased cancer incidence after radioiodine treatment for hyperthyroidism Cancer 109 2007 1972 1979
53. D.A. Huysmans, W.C. Buijs, and M.T. van de Ven et al. Dosimetry and risk estimates of radioiodine therapy for large, multinodular goiters J Nucl Med 37 1996 2072 2079
54. M. Baczyk, R. Junik, and K. Ziemnicka et al. Iodine prophylaxis intensification. Influence on radioiodine uptake and activity of 131I used in the treatment of hyperthyroid patients with Graves' disease Nuklearmedizin 44 2005 197 199
55. A. Vej-Hansen, and B. Nygaard Iodine uptake and the effect of radioiodine treatment-status after the addition of iodine to salt Ugeskrift Læger 167 2005 3684 3687
56. D.A. Huysmans, W.A. Nieuwlaat, and R.J. Erdtsieck et al. Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter J Clin Endocrinol Metabolism 85 2000 3592 3596
57. V.E. Nielsen, S.J. Bonnema, and H. Boel-Jørgensen et al. Recombinant human thyrotropin markedly changes the 131I kinetics during 131I therapy of patients with nodular goiter: an evaluation by a randomized double-blinded trial J Clin Endocrinol Metabolism 90 2005 79 83
58. C.C. Albino, C.O. Mesa Jr., and M. Olandoski et al. Recombinant human thyrotropin as adjuvant in the treatment of multinodular goiters with radioiodine J Clin Endocrinol Metabolism 90 2005 2775 2780
59. L. Braverman, R.T. Kloos, and B. Law Jr. et al. Evaluation of various doses of recombinant human thyrotropin in patients with multinodular goiters Endocr Pract 14 2008 832 839
60. S. Fast, V.E. Nielsen, and S.J. Bonnema et al. Time to reconsider nonsurgical therapy of benign non-toxic multinodular goitre: focus on recombinant human TSH augmented radioiodine therapy Eur J Endocrinol 160 2009 517 528
61. M. Resende, R. Corbo, and M. Vaisman The effect of recombinant human TSH on 123I thyroid uptake after intravenous iodide contrast agent Nucl Med Commun 31 2010 315 319
62. C.C. Albino, G. Paz-Filho, and H. Graf Recombinant human TSH as an adjuvant to radioiodine for the treatment of type 1 amiodarone-induced thyrotoxicosis (AIT) Clin Endocrinol 70 2009 810 811
63. F. Bogazzi, L. Tomisti, and C. Ceccarelli et al. Recombinant human TSH as an adjuvant to radioiodine for the treatment of type 1 amiodarone-induced thyrotoxicosis: a cautionary note Clin Endocrinol 72 2010 133 134
64. M.S. Torres, L. Ramirez, and P.H. Simkin et al. Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects J Clin Endocrinol Metabolism 86 2001 1660 1664
65. M.N. Silva, I.G. Rubio, and R. Romao et al. Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres Clin Endocrinol 60 2004 300 308
66. S. Fast, V.E. Nielsen, and P. Grupe et al. Optimizing 131I uptake after rhTSH stimulation in patients with nontoxic multinodular goiter: evidence from a prospective, randomized, double-blind study J Nucl Med 50 2009 732 737
67. S.J. Bonnema, S. Fast, and V.E. Nielsen et al. Serum thyroxine and age - rather than thyroid volume and serum TSH - are determinants of the thyroid radioiodine uptake in patients with nodular goiter J Endocrinol Investigation 34 2011 e52 e57
68. W.A. Nieuwlaat, A.R. Hermus, and F. Sivro-Prndelj et al. Pretreatment with recombinant human TSH changes the regional distribution of radioiodine on thyroid scintigrams of nodular goiters J Clin Endocrinol Metabolism 86 2001 5330 5336
69. O. Cohen, J. Ilany, and C. Hoffman et al. Low-dose recombinant human thyrotropin-aided radioiodine treatment of large, multinodular goiters in elderly patients Eur J Endocrinol 154 2006 243 252
70. W.A. Nieuwlaat, D.A. Huysmans, and H.C. Van Den Bosch et al. Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter J Clin Endocrinol Metabolism 88 2003 3121 3129
71. G.J. Paz-Filho, C.O. Mesa-Junior, and M. Olandoski et al. Effect of 30 mCi radioiodine on multinodular goiter previously treated with recombinant human thyroid-stimulating hormone Braz J Med Biological Res 40 2007 1661 1670
72. M. Giusti, C. Cappi, and B. Santaniello et al. Safety and efficacy of administering 0.2 mg of recombinant human TSH for two consecutive days as an adjuvant to therapy with low radioiodine doses in elderly out-patients with large nontoxic multinodular goiter Minerva Endocrinol 31 2006 191 209
73. E.R. Cubas, G.J. Paz-Filho, and M. Olandoski et al. Recombinant human TSH increases the efficacy of a fixed activity of radioiodine for treatment of multinodular goitre Int J Clin Pract 63 2009 583 590
74. C.C. Albino, H. Graf, and G. Paz-Filho et al. Radioiodine plus recombinant human thyrotropin do not cause acute airway compression and are effective in reducing multinodular goiter Braz J Med Biological Res 43 2010 303 309
75. D.S. Duick, and H.J. Baskin Utility of recombinant human thyrotropin for augmentation of radioiodine uptake and treatment of nontoxic and toxic multinodular goiters Endocr Pract 9 2003 204 209
76. R. Romao, I.G. Rubio, and E.K. Tomimori et al. High prevalence of side effects after recombinant human thyrotropin-stimulated radioiodine treatment with 30 mCi in patients with multinodular goiter and subclinical/clinical hyperthyroidism Thyroid 19 2009 945 951
77. S. Fast, L. Hegedüs, and P. Grupe et al. Recombinant human thyrotropin-stimulated radioiodine therapy of nodular goiter allows major reduction of the radiation burden with retained efficacy J Clin Endocrinol Metabolism 95 2010 3719 3725
78. C. Ceccarelli, L. Antonangeli, and F. Brozzi et al. Radioiodine (131)I treatment for large nodular goiter: recombinant human thyrotropin allows the reduction of radioiodine (131)I activity to Be administered in patients with low uptake Thyroid 21 2011 759 764
79. M. Giusti, M. Caputo, and I. Calamia et al. Long-term outcome of low-activity radioiodine administration preceded by adjuvant recombinant human TSH pretreatment in elderly subjects with multinodular goiter Thyroid Res 2 2009 10.1186/1756-6614-2-6
80. S.J. Bonnema, S. Fast, and L. Hegedüs Non-surgical approach to the benign nodular goiter: new opportunities by recombinant human TSH-stimulated 131I-therapy Endocrine 40 2011 344 353
81. M. Dietlein, B. Dederichs, and C. Kobe et al. Therapy for non-toxic multinodular goiter: radioiodine therapy as attractive alternative to surgery Nuklearmedizin 45 2006 21 34
82. G. Medeiros-Neto, S. Marui, and M. Knobel An outline concerning the potential use of recombinant human thyrotropin for improving radioiodine therapy of multinodular goiter Endocrine 33 2008 109 117
83. G.J. Paz-Filho, and H. Graf Recombinant human thyrotropin in the management of thyroid disorders Expert Opin Biological Ther 8 2008 1721 1732
84. W.W. Woodmansee, and B.R. Haugen Uses for recombinant human TSH in patients with thyroid cancer and nodular goiter Clin Endocrinol 61 2004 163 173
85. S.J. Bonnema, V.E. Nielsen, and L. Hegedüs Radioiodine therapy in non-toxic multinodular goitre. The possibility of effect-amplification with recombinant human TSH (rhTSH) Acta Oncol 45 2006 1051 1058
86. V.E. Nielsen, S.J. Bonnema, and L. Hegedüs The effects of recombinant human thyrotropin, in normal subjects and patients with goitre Clin Endocrinol 61 2004 655 663
87. S. Pena, S. Arum, and M. Cross et al. 123I thyroid uptake and thyroid size at 24, 48, and 72 hours after the administration of recombinant human thyroid-stimulating hormone to normal volunteers J Clin Endocrinol Metabolism 91 2006 506 510
88. S. Fast, V.E. Nielsen, and P. Grupe et al. Prestimulation with recombinant human thyrotropin (rhTSH) improves the long-term outcome of radioiodine therapy for multinodular nontoxic goiter J Clin Endocrinol Metabolism 97 2012 2653 2660
89. V.E. Nielsen, S.J. Bonnema, and L. Hegedüs Effects of 0.9 mg recombinant human thyrotropin on thyroid size and function in normal subjects: a randomized, double-blind, cross-over trial J Clin Endocrinol Metabolism 89 2004 2242 2247
90. V.E. Nielsen, S.J. Bonnema, and L. Hegedüs Transient goiter enlargement after administration of 0.3 mg of recombinant human thyrotropin in patients with benign nontoxic nodular goiter: a randomized, double-blind, crossover trial J Clin Endocrinol Metabolism 91 2006 1317 1322
91. S. Fast, V.E. Nielsen, and S.J. Bonnema et al. Dose-dependent acute effects of recombinant human TSH (rhTSH) on thyroid size and function: comparison of 0.1, 0.3 and 0.9 mg of rhTSH Clin Endocrinol 72 2010 411 416
92. 131I therapy in benign multinodular goiter. Results from a multicenter international, randomized, placebo-controlled study J Clin Endocrinol Metabolism 96 2011 1368 1376
93. S. Fast, L. Hegedus, and F. Pacini et al. Long-term efficacy of modified-release recombinant human TSH (MRrhTSH) augmented radioiodine (131I) therapy for benign multinodular goiter. Results from a multicenter international, randomized, placebo-controlled dose-selection study Thyroid 2013 [Epub ahead of print]
94. S. Grozinsky-Glasberg, A. Fraser, and E. Nahshoni et al. Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials J Clin Endocrinol Metabolism 91 2006 2592 2599
95. G. Berg, T. Andersson, and L. Sjodell et al. Development of severe thyroid-associated ophthalmopathy in a patient with disseminated thyroid cancer treated with recombinant human thyrotropin/radioiodine and retinoic acid Thyroid 15 2005 1389 1394
96. K.A. Woeber, and L.K. Schwartz Graves ophthalmopathy after radiation treatment of thyroid cancer Endocr Pract 14 2008 419 421
97. S. Savastano, R. Pivonello, and W. Acampa et al. Recombinant thyrotropin-induced orbital uptake of [111In-diethylenetriamine-pentacetic acid-D-Phe1]octreotide in a patient with inactive Graves' ophthalmopathy J Clin Endocrinol Metabolism 90 2005 2440 2444
98. I.G. Rubio, B.H. Perone, and M.N. Silva et al. Human recombinant TSH preceding a therapeutic dose of radioiodine for multinodular goiters has no significant effect in the surge of TSH-receptor and TPO antibodies Thyroid 15 2005 134 139
99. W.A. Nieuwlaat, A.R. Hermus, and H.A. Ross et al. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone J Nucl Med 45 2004 626 633